Jasper Therapeutics, Inc.

Jasper Therapeutics, Inc. (Nasdaq: AMHC) is a clinical-stage biopharmaceutical company that emerged from a business combination with Amplitude Healthcare Acquisition Corporation, a blank-check vehicle sponsored by Amplitude Healthcare Sponsor LLC that completed its IPO in 2021. The company focuses on developing novel therapies to improve and expand the use of hematopoietic stem cell transplantation, with its lead program targeting CD117 as a conditioning agent for patients undergoing stem cell transplant procedures. The combined public entity filed an 8-K with the SEC on August 3, 2026, marking continued regulatory activity for the clinical-stage healthcare issuer. Sign up at SpacDesk for full filing history, sponsor details, and real-time data on AMHC and hundreds of other SPAC-derived companies.